PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

Gilead is laying off 149 workers in Foster City and Roche is laying off 108 workers in Santa Clara, adding to the mounting ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

If all is good, then why do we need new options? Yes, HIV treatment – daily oral regimen – is lifesaving and good – access to ...

Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

FILE - Winnie Byanyima, Executive Director of Oxfam International, attends the 47th annual meeting of the World Economic Forum, WEF, in Davos, Switzerland, Thursday, Jan. 19, 2017. GENEVA (AP ...